Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

AptALS An RNA aptamer-based tool for the detection of pathological protein aggregates in biofluids

Coordinator
Fondazione Istituto Italiano Di Tecnologia, Italy
Runs
1 January 2026 to 31 December 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248691

What the project is doing

In the project's own words, from its summary on CORDIS.

The AptALS project aims to develop a highly sensitive and scalable RNA aptamer-based kit for detecting TDP-43 aggregates, a key biomarker in ALS. The kit consists of 3 main components: (i) biotinylated RNA aptamers that selectively bind aggregated TDP-43, (ii) a detection system (fluorescence or chemiluminescence) to quantify binding events, and (iii) a modular assay format compatible with ELISA-like workflows, allowing seamless integration into clinical laboratories.

By leveraging our patented aptamers, we will validate their performance in a standardized detection assay, ensuring clinical robustness. Unlike conventional antibody-based methods, RNA aptamers offer superior specificity and adaptability, enabling non-invasive, early-stage ALS detection. This innovation fills a critical gap in ALS diagnostics, replacing invasive lumbar punctures and costly neuroimaging with a cost-effective, scalable alternative.

The AptALS project will focus on three key objectives: (i) assay validation, (ii) optimization of detection methods (fluorescence vs. chemiluminescence), and (iii) benchmarking with ALS patient samples. The project is led by a multidisciplinary team with expertise in biophysics, molecular biology, and computational modeling, supported by IIT’s state-of-the-art genomics, proteomics, and microscopy facilities to ensure technical rigor and scalability.

Beyond its scientific impact, AptALS delivers significant societal and economic benefits. Early ALS detection can enable timely intervention, improve patient care, and reduce healthcare costs. The diagnostic kit is designed for B2B distribution, targeting hospitals, diagnostic laboratories, and pharmaceutical companies for clinical trials and patient stratification. Positioned at the forefront of neurodegenerative disease diagnostics, AptALS is poised for strong commercial adoption, bridging the gap between research and real-world clinical application, fostering innovation, and advancing ALS care.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Istituto Italiano Di TecnologiaGenovaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI